Ritter pharmaceuticals inc (RTTR)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Sep'14Jun'14
Operating costs and expenses:
Research and development

1

82

1,036

1,433

3,574

6,079

3,459

1,871

849

752

915

774

432

6,180

2,348

2,880

1,882

675

1,505

47

31

57

6

Patent costs

-

-

-

-

-

-

-

-

-

-

-

-

77

72

98

68

32

83

47

50

62

-

-

Patent costs

3

6

20

69

48

33

59

48

63

-

47

50

-

-

-

-

-

-

-

-

-

29

27

General and administrative

2,209

949

1,122

1,345

1,153

1,467

1,144

1,686

1,125

1,410

1,052

1,144

1,171

1,348

1,091

1,206

1,235

1,544

1,555

2,001

1,302

166

352

Total operating costs and expenses

2,215

1,038

2,180

2,848

4,777

7,580

4,663

3,606

2,038

2,236

2,014

1,969

1,681

7,601

3,539

4,156

3,150

2,303

3,108

2,099

1,396

253

386

Operating loss

-2,215

-1,038

-2,180

-2,848

-4,777

-7,580

-4,663

-3,606

-2,038

-2,236

-2,014

-1,969

-1,681

-7,601

-3,539

-4,156

-3,150

-2,303

-3,108

-2,099

-1,396

-253

-386

Other income:
Other expense

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

1

63

9

0

7

-

-4

Interest income (expense), net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

12

-

Interest income

12

-

-

-

71

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-4

Interest income

-

-

13

33

-

61

17

21

25

21

4

6

7

10

13

16

20

17

18

2

2

-

-

Settlement of accounts payable

535

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total other income

547

593

13

33

71

955

17

21

25

20

4

6

7

10

13

16

21

80

28

2

9

-12

-

Net loss

-1,667

-444

-2,167

-2,815

-4,705

-6,625

-4,646

-3,584

-2,012

-2,216

-2,010

-1,963

-1,673

-7,590

-3,526

-4,139

-3,128

-2,222

-3,080

-2,097

-1,387

-266

-391

Other comprehensive gain:
Unrealized gain on debt securities

-

0

0

-0

1

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss

-1,667

-444

-2,167

-2,815

-4,704

-6,626

-4,646

-3,584

-2,012

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-1,667

-444

-2,167

-2,815

-4,705

-6,625

-4,646

-3,584

-2,012

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cumulative preferred stock dividends

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

178

149

147

147

Accretion of discount of Series C preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-31

-31

-

-

Net loss applicable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,222

-3,080

-2,307

-1,568

-413

-538

Net loss per common share - basic and diluted

-0.05

0.06

-0.23

-0.31

-0.58

-1.68

-0.86

-0.71

-0.41

-1.96

-0.14

-1.41

-1.44

-0.79

-0.41

-0.48

-0.36

4.84

-0.40

-4.18

-3.37

-0.92

-1.18

Weighted average common shares outstanding - basic and diluted

34,910

11,674

9,507

9,042

8,055

5,835

5,373

5,064

4,944

-8,453

14,756

1,395

1,161

10,219

8,585

8,584

8,583

2,977

7,792

551

465

451

456